FGF23 and cholangiocarcinoma: Supportive biomarker data were also documented in one patient with cholangiocarcinoma after tinengotinib therapy that showed a 4.8-fold increase in FGF-23 (a marker of FGFR inhibition) plasma levels accompanied by 30% reduction in target tumor size at cycle 3 day 1.